Back to Top Skip to main content

Shingles

Shingles

Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox. Shingles infection occurs when the virus reactivates decades after initial infection, and affects approximately one in three persons in the general population during their lifetime. Shingles is characterized by a localized, often severely painful cutaneous eruption that can last weeks or months, and occurs most frequently in older adults.

Shingles vaccine is licensed for adults ages 50 and older. The current recommendation, however, remains to routinely immunize adults 60 years and older with a one-time dose of shingles vaccine. The vaccine can be given to people who have already had an episode of shingles. Check with your doctor to see if the vaccine is needed or if it will be covered by individual medical insurance policies.

Source: Centers for Disease Control and Prevention

You also may be interested in...

Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine — United States, 2017–2018

Report
5/25/2018

Early monitoring indicates that vaccine provides might confuse administration procedures and storage requirements of the older Zostavax and newer Shingrix shingles vaccines.

Recommended Content:

Shingles

QuickStats: Percentage of Adults Aged ≥60 Years Who Ever Had the Shingles Vaccine, by Sex — National Health Interview Survey, 2008–2016

Report
5/18/2018

The percentage of adults aged ≥60 years who ever had the shingles vaccine increased from 6.7% in 2008 to 33.4% in 2016. Women were more likely than men to have had the shingles vaccine.

Recommended Content:

Shingles

MMQC-18-1648 GlaxoSmithKline Shingrix Shortage

Publication
5/10/2018

The purpose of this message is to provide disposition instructions on shipping delays for Shingrix (zoster recombinant, adjuvanted) vaccine.

Recommended Content:

Shingles

MMQC-18-1396 Pharmaceutical Reverse Distributor Program Acceptance of Live Attenuated Shingles Vaccine (Zostavax)

Publication
3/27/2018

Medical treatment facilities (MTFs) may now turn in soon-to-expire Zostavax shingles vaccine to potentially receive a credit on their Prime Vendor account.

Recommended Content:

Shingles

Shingrix vaccine storage labels

Publication
2/7/2018

Examples of proper storage, handling and reconstitution of Shingrix recombinant shingles vaccine.

Recommended Content:

Shingles

Shingles Disease and Shingles Vaccine

Fact Sheet
2/5/2018

This information paper describes the Herpes Zoster (Shingles) disease and vaccine to prevent it.

Recommended Content:

Shingles

Standing Orders for Administering Recombinant Zoster Vaccine (RZV) to Adults

Publication
2/1/2018

Standing orders for the administration of the recently licensed SHINGRIX vaccine.

Recommended Content:

Shingles

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Report
1/26/2018

Revised recommendations for use of shingles vaccines following the October 2017 approval of a new vaccine.

Recommended Content:

Shingles

Varicella (Herpes) Zoster Vaccine Update - Recommendations and Usage

Policy
  • Identification #: N/A
  • Date: 7/25/2011
  • Type: Directives
  • Topics: Shingles
<< < 1 > >> 
Showing results 1 - 9 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.